Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant will receive $611,000. The contract can be extended to up to a total of $4.6 million over three years to support OPNT003 through an NDA submission.

Opiant also received this year a $7.4 million grant from NIH's National Institute on Drug Abuse (NIDA) to support development of OPNT003...